Skip to main content
Home
     
  • Our Story
    • Our Founders
    • Our Mission
    • Governance
    • Partnerships
  • Our Impact
    • Countries
    • Programs
    • Impact
    • Research
  • Support Our Work
    • Donate
      • Inspired Giving
      • Monthly Donations
      • Gifts of Stock or Securities
      • Donate in Honor or Memory
      • Planned Giving
      • More Ways to Give
      • Manage Your Online Giving
      • View Your Contribution History
      • Leadership Giving Society
    • Join Us
      • Fundraise
      • PIH Engage
  • News

Donate Now  

Share

Expanding New Drugs for TB (endTB)

Posted on May 20, 2015
Expanding New Drugs for TB (endTB)

"endTB" is an innovative project using new tuberculosis (TB) drugs implemented by the international organizations Partners In Health (PIH) Medecins Sans Frontieres (MSF), Interactive Research and Development (IRD), and funded by UNITAID with a four-year, 60.4 million USD grant. This project aims to produce concrete results in the form of more effective and better-tolerated regimens for MDR-TB that will in turn lead to greater access.

For the first time in over 40 years, two new anti-TB drugs (bedaquiline and delamanid) have been developed. While the WHO has produced interim policy recommendations on their clinical use, very few patients have received these new drugs as part of national TB treatment programs. The endTB Project will provide these two new drugs in a closely monitored multi-country cohort of 2,600 patients in 15 countries. The endTB Project will also implement a clinical trial among 600 additional patients to identify novel treatment regimens that are shorter and less toxic than current MDR-TB treatment regimens. Through these activities, the end TB project will:

1) Generate evidence of safety and efficacy of new TB drugs.

2) Accelerate uptake of new TB drugs and novel MDR-TB regimens.

3) Facilitate change in evidence-based WHO recommendations.

All endTB patients will benefit from a strong pharmacovigilance system and will be actively monitored for potential adverse events through a regular schedule of clinical evaluations and laboratory monitoring tests that is consistent with WHO recommendations.

 

Related links:

Learn about Partners In Health's tuberculosis work

Peru: Study Aims to Reveal How TB Spreads

 

 

 

 

 

Country
Lesotho, Peru
Programs
Tuberculosis
Related Categories
  • Tuberculosis donation ask (Peru photo)

    For us, tuberculosis treatment means food and shelter – not just drugs.

    More than medicine.
    Give Now
  • TB Quiz Tout (Russia - March 2015)

    Take our quick, four-question TB quiz.

    Test your knowledge
    Take the quiz

You may also be interested in

  • Sheila Davis walks to helicopter during Ebola response in Liberia
    Oct 16, 2019

    CEO Dr. Sheila Davis Reflects on 5-Year ...

  • MDR-TB survivor poses outside hospital where she was cured
    Oct 10, 2019

    "The Right Medicine": Young Woman Triump...

  • Emric Ansu outside his home in Koidu, Sierra Leone
    Aug 29, 2019

    Students in Sierra Leone Share Stories a...

Sign up for email updates

88.4% of your gift goes straight to those in need.

Donate Now  

Donations can be made by Mastercard, VISA, Discover, American Express or PayPal.
Partners In Health, 800 Boylston Street, Suite 300, Boston, MA. 02199
Phone: +1 (857) 880-5100
info@pih.org
Partners In Health (PIH) is a 501(c)(3) nonprofit corporation, EIN 04-3567502.
PIH® is a registered trademark of Partners In Health.
© 2009 - 2019 Partners In Health. All Rights Reserved.

Charity Navigator Four Star Charity

  • Contact Us
  • Join the Team
  • Media Coverage
  • Information for Suppliers
  • Press Releases
  • PIH Canada
  • PIH Alumni Network
  • Terms of Use
  • Cookie Policy
  • Donor Privacy Policy
Discourse & tools for global health professionals:
Knowledge Center